MBX Biosciences, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
MBX Biosciences, Inc. (MBX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 5.01 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- MBX Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 4.86M shares, a 12.83% increase year-over-year.
- MBX Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 4.31M shares, a 76.07% decline year-over-year.
- MBX Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 17.99M shares.
- MBX Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 4.63M shares, a 31.81% increase from fiscal 2024.
- MBX Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 3.52M shares, a 80.24% decline from fiscal 2023.
- MBX Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 17.79M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 5.01M shares 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | 4.86M shares 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | 4.63M shares 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | 4.60M shares 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | 4.31M shares 10-Q · filed 2026-08-06 | 4.35M shares 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | 4.31M shares 10-Q · filed 2026-05-07 | ||||
| 2024-12-31 | 3.52M shares 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | 3.59M shares 10-Q · filed 2025-11-06 | ||||
| 2024-06-30 | 18.11M shares 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | 17.99M shares 10-Q · filed 2025-05-12 | ||||
| 2023-12-31 | 17.79M shares 10-K · filed 2025-03-17 | ||||
| 2023-09-30 | 17.75M shares 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |